Tadalafil Tablet
Product Images NDC 70954-435

Product Visual Gallery

This gallery contains 12 technical images submitted to the FDA as part of the official labeling for Tadalafil (NDC 70954-435). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Ani Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

New1 (Fig 2)

A set of two line graphs showing the change in systolic blood pressure (mmHg) over 24 hours after dosing. The top graph depicts standing systolic blood pressure changes, and the bottom graph shows supine systolic blood pressure changes. Both graphs compare Tadalafil 20 mg combined with doxazosin 8 mg versus placebo with doxazosin 8 mg over time post-dose (hours).*

FDA Label Image

Three (Fig 3new)

A line graph depicting the effect of tadalafil on systolic blood pressure (BP) measured in mmHg over 12 hours after administration. Multiple lines represent different conditions including 20 mg tadalafil combined with 8 mg doxazosin, placebo combined with 8 mg doxazosin, and their values at different times. The x-axis shows time in hours and the y-axis represents changes in systolic BP.*

FDA Label Image

Seven (Fig 7new)

A line graph depicting mean change from baseline over 26 weeks of therapy comparing Tadalafil/Finasteride combination versus Placebo/Finasteride. The x-axis represents weeks of therapy (0, 4, 12, 26), and the y-axis shows least-squares mean change from baseline. The graph shows greater improvement with Tadalafil/Finasteride at all measured intervals.*

FDA Label Image

Figure-1 (Figure 1)

A set of four line graphs showing the difference in blood pressure (BP) measurements between Tadalafil and Placebo over time in hours. The graphs depict changes in Standing Systolic BP, Standing Diastolic BP, Supine Systolic BP, and Supine Diastolic BP. Each graph shows a trend of differences measured from 0 to 96 hours, with vertical error bars indicating variability.*

FDA Label Image

Figure-4 (Figure 4)

A line graph showing plasma tadalafil concentration (µg/L) over time (hours) after different dosing regimens: single 20-mg dose, single 5-mg dose, and once-daily 5-mg dose following 5 consecutive days. The graph includes error bars indicating variability or standard deviation.*

FDA Label Image

Figure-5 (Figure 5)

A line graph depicting the change from baseline in the IPSS total score over 12 weeks of treatment comparing Cialis 5 mg and placebo. The x-axis represents the duration of treatment in weeks (0, 4, 8, 12), and the y-axis shows the change from baseline in IPSS total score, ranging from 0 to -6. The graph shows a greater reduction in score for Cialis 5 mg compared to placebo, with a statistically significant difference indicated at week 12 (p<0.01).*

FDA Label Image

Figure-6 (Figure 6)

A line graph comparing change from baseline in IPSS total score over a 12-week treatment duration for Cialis 5 mg versus placebo. The y-axis shows change from baseline scores, and the x-axis shows treatment weeks. Data points indicate greater score reductions with Cialis 5 mg compared to placebo, with statistical significance at weeks 4 and 12 (p<0.01).*

FDA Label Image

Figure-8 (Figure 8)

A line graph comparing change from baseline in IPSS (International Prostate Symptom Score) total score over 12 weeks of treatment between Cialis 5 mg and placebo groups. The x-axis represents duration of treatment in weeks (0, 2, 4, 8, 12), and the y-axis shows change from baseline in IPSS total score, with both groups showing a decrease, Cialis 5 mg showing a greater reduction over time. Significant difference indicated with an asterisk for p<0.01.*

FDA Label Image

Container-2 (Label 10 mg)

Label for Tadalafil Tablets, USP 10 mg oral tablets, packaged as 30 tablets. The label includes dosage instructions, storage conditions, and warnings. Manufactured by Novitium Pharma LLC, the label features a green 10 mg strength indicator and the NDC 70954-434-10.*

FDA Label Image

Container-3 (Label 20 mg)

Label for Tadalafil Tablets USP 20 mg, oral tablets in a 30-tablet package. The label states tablets should not be split and the entire dose should be taken. Manufactured by Novitium Pharma LLC with issuance date 04/2022. Storage instructions and warnings are also present, along with a barcode and NDC 70954-435-10.*

FDA Label Image

Container-1 (Label 5 mg)

Tadalafil Tablets, USP 5 mg oral tablets label showing a 30-tablet count. The label includes storage instructions, a warning to keep out of reach of children, dosage advisories, and manufacturer information for Novitium Pharma LLC. The label displays the NDC 70954-433-10 and features a barcode.*

FDA Label Image

Structure (Structure)

Chemical structure of tadalafil, showing the molecular arrangement with benzene rings, heteroatoms, and functional groups characteristic of this active pharmaceutical ingredient.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.